Yesterday, the German government (via KfW) secured a 25.1% "blocking minority" in TenneT's German operations. The €3.3bn deal ends years of negotiations between Germany and the Netherlands. The deal is struck at the same equity value following the capital contribution (46%) from ABP, GIC and Norges Bank in 09/25 at a total equity value of 13.3bn. TenneT NL will hold the remaining 28.9%. We understand from the Handelsblatt that KfW will invest an additional €1.7bn before 2035. TenneT GE will no...
Novo Nordisk initiates 2026 share repurchase programme Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S’ overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Novo Nordisk A/S today initiates a new share repurchase programme for an amount up to DKK 3.8 billion, to be executed during the trading period 4 February 2026 through 4 May 2026. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. A maximum of 400,000,000 B ...
Novo Nordisk has published its annual report for 2025 Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report. The report is available here: and is attached in iXBRL format. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 8...
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025 Bagsværd, Denmark 3 February 2026 - Financial report for the period 1 January 2025 to 31 December 2025 Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates (CER) to DKK 127.7 billion. Had Novo Nordisk not incurred costs related to the company-wide transformation of around DKK 8 billion, operating profit would have increased by 6% in Danish kroner and 13% at CER.Sales in US Operations increased by 3% in Danish kroner (8% at CER...
Novo Nordisk releases 2026 sales and operating profit outlook Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. 2025 sales and operating profit growth at CERIn 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and 4 to 7% operating profit growth1. Sales in US Operations were positively impacted by gross-to-net sales adjustments. P...
FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM Maranello (Italy), February 2 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on December 16, 2025, as the first tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “First Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) as...
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1.CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.Superiority was established on both weight loss and HbA1c versus the individual components.In the trial, CagriSema appeared to have a safe and well-tolerated profile consistent wi...
New employee representative on the Board of Directors of Novo Nordisk A/S Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S after 22 years of employment. Therefore, he steps down from the Board of Directors and his alternate, Tanja Villumsen, joins the Board of Directors of Novo Nordisk A/S as employee representative with effect from today. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.